Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Jonathan Zheng Li, M.D.

Co-Author

This page shows the publications co-authored by Jonathan Li and Daniel Kuritzkes.
Connection Strength

6.976
  1. Impact of pre-existing drug resistance on risk of virological failure in South Africa. J Antimicrob Chemother. 2021 05 12; 76(6):1558-1563.
    View in: PubMed
    Score: 0.961
  2. Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS. 2014 Jan 14; 28(2):181-186.
    View in: PubMed
    Score: 0.579
  3. Clinical implications of HIV-1 minority variants. Clin Infect Dis. 2013 Jun; 56(11):1667-74.
    View in: PubMed
    Score: 0.544
  4. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis. 2013 Mar 15; 207(6):893-7.
    View in: PubMed
    Score: 0.537
  5. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS. 2012 Jan 14; 26(2):185-92.
    View in: PubMed
    Score: 0.504
  6. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011 Apr 06; 305(13):1327-35.
    View in: PubMed
    Score: 0.477
  7. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clin Infect Dis. 2020 04 10; 70(8):1636-1642.
    View in: PubMed
    Score: 0.223
  8. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963.
    View in: PubMed
    Score: 0.202
  9. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018 08 31; 128(9):4074-4085.
    View in: PubMed
    Score: 0.199
  10. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA. J Virol. 2018 06 15; 92(12).
    View in: PubMed
    Score: 0.196
  11. Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. Pathog Immun. 2017; 2(3):431-445.
    View in: PubMed
    Score: 0.189
  12. Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. J Infect Dis. 2017 07 15; 216(2):254-262.
    View in: PubMed
    Score: 0.184
  13. Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials. . 2016 07 01; 72(3):310-3.
    View in: PubMed
    Score: 0.172
  14. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016 Jan 28; 30(3):343-53.
    View in: PubMed
    Score: 0.167
  15. Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics. Open Forum Infect Dis. 2015 Jan; 2(1):ofu117.
    View in: PubMed
    Score: 0.155
  16. Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study. AIDS. 2014 Nov 28; 28(18):2649-57.
    View in: PubMed
    Score: 0.154
  17. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014 Sep 02; 161(5):319-27.
    View in: PubMed
    Score: 0.151
  18. Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. PLoS One. 2014; 9(3):e90485.
    View in: PubMed
    Score: 0.146
  19. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013 Jun 01; 207(11):1694-702.
    View in: PubMed
    Score: 0.136
  20. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J Virol Methods. 2012 Dec; 186(1-2):68-72.
    View in: PubMed
    Score: 0.132
  21. Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption. J Acquir Immune Defic Syndr. 2012 Sep 01; 61(1):19-22.
    View in: PubMed
    Score: 0.132
  22. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother. 2012 Nov; 56(11):5998-6000.
    View in: PubMed
    Score: 0.131
  23. Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One. 2012; 7(3):e34134.
    View in: PubMed
    Score: 0.128
  24. Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis. 2011 Apr 01; 203(7):976-83.
    View in: PubMed
    Score: 0.119
  25. SARS-CoV-2 RNA Detection by a Cellphone-Based Amplification-Free System with CRISPR/CAS-Dependent Enzymatic (CASCADE) Assay. Adv Mater Technol. 2021 Jul 19; 2100602.
    View in: PubMed
    Score: 0.061
  26. Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infect Dis. 2021 Aug; 8(8):ofab153.
    View in: PubMed
    Score: 0.060
  27. Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning. ACS Nano. 2021 01 26; 15(1):665-673.
    View in: PubMed
    Score: 0.058
  28. Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. J Infect Dis. 2020 11 09; 222(11):1837-1842.
    View in: PubMed
    Score: 0.058
  29. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020 10 30; 11(1):5493.
    View in: PubMed
    Score: 0.058
  30. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 04; 6(4):e259-e268.
    View in: PubMed
    Score: 0.052
  31. Rapid, label-free CD4 testing using a smartphone compatible device. Lab Chip. 2017 08 22; 17(17):2910-2919.
    View in: PubMed
    Score: 0.046
  32. Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion. AIDS. 2014 Jun 19; 28(10):1539-41.
    View in: PubMed
    Score: 0.037
  33. Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis. 2010 Nov 15; 202(10):1478-81.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.